InvestSMART

Prana Biotechnology Limited (ASX: PBT) - Announcements

Current share price for PBT : $0.049 0.002 (4.26%)+

ASX company news and announcements for Prana Biotechnology Limited (PBT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Prana Biotechnology Limited (PBT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Prana Biotechnology Limited (PBT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Prana Biotechnology Limited (PBT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- New benchmark test to assess HD patients in clincial trials 19 Jun 2013 12:17PM $0.230 $0.049 fallen by 78.70%
- Appendix 4C - quarterly 29 Apr 2013 5:03PM $0.205 $0.049 fallen by 76.10%
- Share Purchase Plan 2013 Offer Document 11 Apr 2013 5:18PM $0.210 $0.049 fallen by 76.67%
- Prana announces $5.8 million R&D refund 4 Apr 2013 3:45PM $0.215 $0.049 fallen by 77.21%
- Prana Provides Clinical Trials Safety and Progress Update 3 Apr 2013 4:13PM $0.210 $0.049 fallen by 76.67%
- Prana Announces Successful A$7 milion Capital Raising 27 Mar 2013 7:10PM $0.225 $0.049 fallen by 78.22%
- Trading Halt 27 Mar 2013 9:03AM $0.225 $0.049 fallen by 78.22%
- Prana details PBT2 data on reduced Tau Cognitive Impairment 8 Mar 2013 4:33PM $0.235 $0.049 fallen by 79.15%
- Response to ASX Query 7 Mar 2013 9:57AM $0.235 $0.049 fallen by 79.15%
- Pranas PBT434 Inhibits PD Protein & Brain Cell Death 6 Mar 2013 10:29AM $0.225 $0.049 fallen by 78.22%
- Prana's PBT2 Reduces Tau Related Cognitive Impairment 4 Mar 2013 3:12PM $0.250 $0.049 fallen by 80.40%
- Appendix 4D 27 Feb 2013 4:24PM $0.210 $0.049 fallen by 76.67%
- Appendix 4C - quarterly 31 Jan 2013 4:23PM $0.210 $0.049 fallen by 76.67%
- Prana Completes Recruitment in Huntington Trial 19 Dec 2012 9:42AM $0.210 $0.049 fallen by 76.67%
- Journal of Huntington's Disease Publishes Benefits of PBT2 13 Dec 2012 10:19AM $0.215 $0.049 fallen by 77.21%
- New York Academy of Sciences Symposium Discusses PBT2 6 Dec 2012 11:39AM $0.215 $0.049 fallen by 77.21%
- Prana Completes Recruitment in Alzheimer's Trial 27 Nov 2012 9:30AM $0.220 $0.049 fallen by 77.73%
- Prana Provides Huntington Disease Trial Update 14 Nov 2012 2:20PM $0.215 $0.049 fallen by 77.21%
- Appendix 4C - quarterly 29 Oct 2012 4:44PM $0.280 $0.049 fallen by 82.50%
- Prana Announces A$6.0 Million Capital Raising 1 Oct 2012 7:31PM $0.225 $0.049 fallen by 78.22%
- Trading Halt 1 Oct 2012 9:53AM $0.225 $0.049 fallen by 78.22%
- Prana Receives Recommendation to Proceed with Clinical Trial 12 Sep 2012 9:59AM $0.215 $0.049 fallen by 77.21%
- Significant Promise in the Fight Against Alzheimer's Disease 11 Sep 2012 10:02AM $0.225 $0.049 fallen by 78.22%
- Appendix 4E - Preliminary Financial Report 31 Aug 2012 4:47PM $0.170 $0.049 fallen by 71.18%
- Prana's Parkinson's drug meets development milestone 30 Aug 2012 9:50AM $0.180 $0.049 fallen by 72.78%

176 - 200 of 331 results

Page 8 of 14

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.